News for NMDBF Stock

NeonMind Announces Positive Preclinical Results Demonstrating the Efficacy of Psilocybin in Reducing Weight Gain in Obese Animal Subjects NeonMind Files New Provisional Patent Application Covering Novel Mechanism of Weight Loss NeonMind Reports Business Highlights on Partnership Activities, Clinical Pipeline and Corporate Developments NeonMind and BioScript Solutions Announce Strategic Partnership Expanding NeonMind's Specialty Clinic Network for Interventional Psychiatry Treatments NeonMind Appoints Canadian Medical Leader in Anesthesiology, Dr. Daniel Bainbridge, MD, FRCPC to Its Specialty Clinics Advisory Board NeonMind to Present at H.C. Wainwright Bioconnect Conference NeonMind to Present at H.C. Wainwright 2nd Annual Psychedelics Virtual Conference NeonMind Announces Successful Completion of Pre-IND Consultation with FDA on Clinical Path for Obesity Drug Candidate NEO-001 NeonMind to Participate in Panel Discussion at Lift & Co. Expo's Psychedelics Business Summit on November 19, 2021 NeonMind Biosciences Named as a Top Industry Innovator in Inaugural Issue of Psychedelia Magazine NeonMind to Present at the KCSA Psychedelics Virtual Investor Conference on October 14th NeonMind Advances Strategy for Specialty Clinic Launch NeonMind Strengthens its Specialty Clinics Advisory Board with Appointment of Mood Disorders and Ketamine Expert Dr. Gustavo Vazquez, MD, PhD. NeonMind Appoints Ketamine and Neurostimulation Expert Dr. Roumen Milev, MD, PhD to Specialty Clinic Advisory Board NeonMind Announces Divestiture of Consumer Related and Other Non-Core Assets NeonMind to Present at H.C. Wainwright 23rd Annual Global Investment Conference NeonMind Announces DTC Eligibility NeonMind Receives Health Canada Approval for its Functional Mushroom Formulation 'Mindful Blend' NeonMind Announces Corporate Update and Strategic Reorganization of its Pharmaceutical Division Dr. Sagar Parikh, MD Appointed to NeonMind Specialty Clinics Advisory Board NeonMind Provides Integrated Drug Development Plan Update for NEO-001 to Treat Obesity NeonMind Announces Launch of Functional Mushroom Coffees as Dietary Supplements in the US